Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 106308-44-5 | Product Number: R0143
Rufinamide

Purity: >98.0%(HPLC)
Synonyms:
- 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Product Documents:
Size | Unit Price | Belgium | Japan* |
---|---|---|---|
25MG |
€16.00
|
1 | 6 |
100MG |
€38.00
|
Contact Us | 3 |
1G |
€237.00
|
1 | 4 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Product Number | R0143 |
Purity / Analysis Method | >98.0%(HPLC) |
Molecular Formula / Molecular Weight | C__1__0H__8F__2N__4O = 238.20 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
CAS RN | 106308-44-5 |
Reaxys Registry Number | 13495800 |
PubChem Substance ID | 253662493 |
Merck Index (14) | 8293 |
MDL Number | MFCD00865314 |
Specifications
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Elemental analysis(Nitrogen) | 22.50 to 24.50 % |
Melting point | 239.0 to 243.0 °C |
Properties (reference)
Melting Point | 241 °C |
Solubility in water | Insoluble |
Solubility (insoluble in) | Ethanol |
GHS
Pictogram |
![]() |
Signal Word | Warning |
Hazard Statements | H336 : May cause drowsiness or dizziness. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust. P271 : Use only outdoors or in a well-ventilated area. P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell. P403 + P233 : Store in a well-ventilated place. Keep container tightly closed. P405 : Store locked up. |
Related Laws:
Transport Information:
HS Number | 2933998090 |
Application
Rufinamide: A Broad-Spectrum Anticonvulsant Agent
Rufinamide is an antiepileptic agent with a triazole derivative structure. It is showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action of rufinamide is considered to be the modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide is extensively metabolized in the liver by non-CYP450 enzymes. Recently, rufinamide is in development for the adjunctive treatment of refractory epilepsy, Lennox-Gastaut syndrome (LGS). (The product is for research purpose only.)
References
- Rufinamide (a review)
- Rufinamide: a new anti-epileptic medication (a review)
- Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome (a review)
- Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions (a review)
- Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.